Table II. Regimen details for patients with haematological malignancies who received HEC or MEC.
ABVD, Doxorubicin, bleomycin, vinblastine, and dacarbazine; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; VCD, bortezomib, cyclophosphamide, and dexamethasone.